
    
      Evaluation of remission status will take place 4 months after treatment. In addition, it will
      be tested whether patients with non-optimal response will have a benefit from a second cycle
      of cladribine.

      Non-optimal response is: patients with detectable residual disease; achievement of partial
      remission or detectable residual infiltration in the bone marrow.
    
  